Dare Bioscience Reports Positive Interim Results for Ovaprene Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Dare Bioscience announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating Ovaprene, its investigational monthly, hormone-free intravaginal contraceptive. The trial's independent data safety monitoring board conducted a planned interim analysis and recommended the study continue without modification. Interim data show approximately 9% of the women treated experienced a pregnancy, consistent with expectations. No new types of adverse events or tolerability concerns were identified. "We are encouraged by these interim results and this second positive DSMB review," said Sabrina Martucci Johnson, president and CEO of Dare Bioscience. "Millions of women in the U.S. are seeking effective, hormone-free birth control, and Ovaprene has the potential to address a significant unmet need and transform the contraceptive landscape. We look forward to advancing toward the primary endpoint analysis as we complete the study."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DARE
Wall Street analysts forecast DARE stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.280
Low
8.00
Averages
10.00
High
12.00
Current: 2.280
Low
8.00
Averages
10.00
High
12.00
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Daré (DARE) Q4 2025 Earnings Call Transcript
See More
Daré Bioscience Initiates Phase 2 Clinical Trial for DARE-HPV
- Clinical Trial Launch: Daré Bioscience has announced the initiation of its Phase 2 clinical trial for DARE-HPV, aimed at evaluating a novel localized self-administered therapy for clearing high-risk HPV infections, potentially offering new treatment options for six million women annually.
- Funding Support: The project is backed by a $10 million contract from the U.S. government’s ARPA-H, with $9 million received to date, highlighting governmental commitment to innovation in women's health and potentially paving the way for further investments.
- Study Design: This trial is a randomized, double-blind, placebo-controlled study planned to involve approximately 100 women over a 21-day treatment period, primarily assessing HPV clearance rates at three months post-treatment, which could redefine current treatment paradigms if successful.
- Market Potential: If approved, DARE-HPV would be the first pharmacologic treatment for high-risk HPV infection, addressing a significant unmet need and potentially reducing cervical cancer incidence in the U.S., thus holding substantial public health significance.
See More
Daré Bioscience Q1 2026 Earnings Call Insights
- Financial Overview: Daré Bioscience ended Q1 2026 with approximately $18.5 million in cash and cash equivalents and $0.5 million in working capital, indicating tight financial management as the company faces upcoming product revenue and financing needs.
- Revenue Expectations: The company expects to begin recording product revenue from DARE to PLAY in Q3 2026, while Flora Sync LF5 is anticipated to generate revenue starting in June 2026, marking a significant commercial milestone as the first direct product revenue.
- Clinical Trial Progress: The Ovaprene clinical trial received a second consecutive recommendation to continue without modification, with approximately 9% of women experiencing pregnancy, providing positive support for future FDA approval and potentially enhancing the company's competitiveness in the consumer health product market.
- Financing Needs Warning: Management highlighted in the Q&A that “we will need to raise” capital, indicating that without expected revenue and grant disbursements, the current cash runway is insufficient for 12 months, underscoring potential liquidity risks for the company.
See More
Dare Bioscience Q1 Earnings Exceed Expectations
- Earnings Highlights: Dare Bioscience reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.10, indicating potential improvements in the company's profitability outlook.
- Revenue Performance: The company generated $15.45M in revenue for Q1, a 39.2% year-over-year decline, yet it surpassed market expectations of $15.42M, demonstrating relative competitive strength amid challenges.
- Cash Position: As of March 31, 2026, Dare had approximately $18.5M in cash and cash equivalents, along with about $0.5M in working capital, reflecting solid financial management practices.
- Future Strategy: Dare Bioscience is implementing a multiplatform strategy aimed at launching new revenue streams in 2026, which is expected to enhance its market position and address current revenue challenges.
See More
Dare Bioscience Set to Announce Q1 Earnings
- Earnings Announcement Schedule: Dare Bioscience (DARE) is set to release its Q1 2023 earnings on May 14th after market close, with consensus EPS estimate at -$0.30, reflecting a 40% year-over-year improvement.
- Revenue Expectations: The anticipated revenue for Q1 is $0.03 million, representing a staggering 99.9% year-over-year decline, indicating significant challenges in revenue growth that may impact investor confidence.
- Historical Performance Review: Over the past year, DARE has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, suggesting a degree of stability in the company's financial performance.
- Estimates Revision Dynamics: In the last three months, EPS estimates saw one upward revision with no downward adjustments, while revenue estimates experienced one downward revision, reflecting a cautious market outlook on the company's future performance.
See More
Daré Bioscience Q4 2025 Earnings Call Insights
- Product Launch Progress: Daré Bioscience's DARE to PLAY topical sildenafil cream began pre-fulfillment prescribing in February 2026 and is now available in all 50 states, marking a significant step in the company's strategic focus on women's health, which is expected to create substantial shareholder value.
- Strong Financial Position: As of year-end 2025, the company reported approximately $24.7 million in cash and cash equivalents and $3.4 million in working capital, demonstrating financial resilience in R&D and marketing efforts, providing a solid foundation for future product launches.
- Pipeline Update: The Phase III trial for Ovaprene is anticipated to complete enrollment in 2026, with data readout expected in 2027, while DARE-HPV is advancing to Phase II clinical studies in 2026, indicating ongoing progress in the company's commitment to women's health and potential for innovative products.
- Market Strategy Optimization: The company is leveraging a digitally native commercial model with Medvantx for product fulfillment and plans to enhance market penetration through strategic distribution partnerships, ensuring a competitive edge in a rapidly evolving market.
See More
Daré (DARE) Q4 2025 Earnings Call Transcript
See More
Daré Bioscience Initiates Phase 2 Clinical Trial for DARE-HPV
- Clinical Trial Launch: Daré Bioscience has announced the initiation of its Phase 2 clinical trial for DARE-HPV, aimed at evaluating a novel localized self-administered therapy for clearing high-risk HPV infections, potentially offering new treatment options for six million women annually.
- Funding Support: The project is backed by a $10 million contract from the U.S. government’s ARPA-H, with $9 million received to date, highlighting governmental commitment to innovation in women's health and potentially paving the way for further investments.
- Study Design: This trial is a randomized, double-blind, placebo-controlled study planned to involve approximately 100 women over a 21-day treatment period, primarily assessing HPV clearance rates at three months post-treatment, which could redefine current treatment paradigms if successful.
- Market Potential: If approved, DARE-HPV would be the first pharmacologic treatment for high-risk HPV infection, addressing a significant unmet need and potentially reducing cervical cancer incidence in the U.S., thus holding substantial public health significance.
See More
Daré Bioscience Q1 2026 Earnings Call Insights
- Financial Overview: Daré Bioscience ended Q1 2026 with approximately $18.5 million in cash and cash equivalents and $0.5 million in working capital, indicating tight financial management as the company faces upcoming product revenue and financing needs.
- Revenue Expectations: The company expects to begin recording product revenue from DARE to PLAY in Q3 2026, while Flora Sync LF5 is anticipated to generate revenue starting in June 2026, marking a significant commercial milestone as the first direct product revenue.
- Clinical Trial Progress: The Ovaprene clinical trial received a second consecutive recommendation to continue without modification, with approximately 9% of women experiencing pregnancy, providing positive support for future FDA approval and potentially enhancing the company's competitiveness in the consumer health product market.
- Financing Needs Warning: Management highlighted in the Q&A that “we will need to raise” capital, indicating that without expected revenue and grant disbursements, the current cash runway is insufficient for 12 months, underscoring potential liquidity risks for the company.
See More
Dare Bioscience Q1 Earnings Exceed Expectations
- Earnings Highlights: Dare Bioscience reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.10, indicating potential improvements in the company's profitability outlook.
- Revenue Performance: The company generated $15.45M in revenue for Q1, a 39.2% year-over-year decline, yet it surpassed market expectations of $15.42M, demonstrating relative competitive strength amid challenges.
- Cash Position: As of March 31, 2026, Dare had approximately $18.5M in cash and cash equivalents, along with about $0.5M in working capital, reflecting solid financial management practices.
- Future Strategy: Dare Bioscience is implementing a multiplatform strategy aimed at launching new revenue streams in 2026, which is expected to enhance its market position and address current revenue challenges.
See More
Dare Bioscience Set to Announce Q1 Earnings
- Earnings Announcement Schedule: Dare Bioscience (DARE) is set to release its Q1 2023 earnings on May 14th after market close, with consensus EPS estimate at -$0.30, reflecting a 40% year-over-year improvement.
- Revenue Expectations: The anticipated revenue for Q1 is $0.03 million, representing a staggering 99.9% year-over-year decline, indicating significant challenges in revenue growth that may impact investor confidence.
- Historical Performance Review: Over the past year, DARE has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, suggesting a degree of stability in the company's financial performance.
- Estimates Revision Dynamics: In the last three months, EPS estimates saw one upward revision with no downward adjustments, while revenue estimates experienced one downward revision, reflecting a cautious market outlook on the company's future performance.
See More
Daré Bioscience Q4 2025 Earnings Call Insights
- Product Launch Progress: Daré Bioscience's DARE to PLAY topical sildenafil cream began pre-fulfillment prescribing in February 2026 and is now available in all 50 states, marking a significant step in the company's strategic focus on women's health, which is expected to create substantial shareholder value.
- Strong Financial Position: As of year-end 2025, the company reported approximately $24.7 million in cash and cash equivalents and $3.4 million in working capital, demonstrating financial resilience in R&D and marketing efforts, providing a solid foundation for future product launches.
- Pipeline Update: The Phase III trial for Ovaprene is anticipated to complete enrollment in 2026, with data readout expected in 2027, while DARE-HPV is advancing to Phase II clinical studies in 2026, indicating ongoing progress in the company's commitment to women's health and potential for innovative products.
- Market Strategy Optimization: The company is leveraging a digitally native commercial model with Medvantx for product fulfillment and plans to enhance market penetration through strategic distribution partnerships, ensuring a competitive edge in a rapidly evolving market.
See More
